VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Kao Corporation vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Kao Corporation
4452 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Kao Corporation's moat claims, evidence, and risks.
View 4452 analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 60 / 100 for Kao Corporation).
- Segment focus: Kao Corporation has 5 segments (33.5% in Hygiene Living Care Business); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: Kao Corporation has 5 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Kao Corporation
Hygiene Living Care Business
Household & fabric care and sanitary consumer packaged goods
Japan and Asia (with select global brands)
Consumers (retail)
Branded manufacturer
33.5%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Kao Corporation strengths
Gilead Sciences, Inc. strengths
Segment mix
Kao Corporation segments
Full profile >Hygiene Living Care Business
Oligopoly
Health Beauty Care Business
Competitive
Cosmetics Business
Competitive
Business Connected Business
Competitive
Chemical Business
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.